Shares shifted as Nasdaq moved to formally erase Aditxt Inc. (ADTX) from its exchange, filing Form 25 with the SEC to complete a delisting that caps months of regulatory failure. For any remaining shareholders, the question is no longer whether Aditxt survives on a major exchange — it won't — but whether the company can sustain any value at all from the OTC wasteland.
A Trail of Reverse Splits and Broken Promises Led Here. Aditxt's stock traded below the $1.00 minimum bid price for 30 consecutive business days between March and May 2026. Normally, companies get 180 days to fix that. Aditxt was denied that grace period because it had already executed reverse stock splits with a cumulative ratio exceeding 250-to-1 over two years.
The company pushed through yet another 1-for-27 reverse split in May 2026 — a desperate move that failed to hold the price above $1.00. The stock now trades at fractions of a penny.
Negative $35 Million in Shareholder Equity Sealed the Deal. As of March 31, 2026, Aditxt reported stockholders' equity of negative $35.2 million — far below Nasdaq's $2.5 million minimum requirement.
The Hearings Panel ruled the company failed to present "a compelling plan to regain compliance" and ordered trading suspended on June 25.
On September 17, Nasdaq formally announced it would file Form 25, making delisting effective ten days after submission.
The Numbers Behind the Collapse Are Staggering. Over the trailing twelve months, Aditxt generated just $14,336 in revenue while posting $53.3 million in losses.
The company holds roughly $269,000 in cash against $4.2 million in debt.
In fiscal year 2025 alone, it burned through a net loss of $43.1 million on $3,000 of revenue — a business generating virtually zero commercial income.
OTC Trading Offers Liquidity in Name Only. Aditxt's market capitalization now sits near $3,900 — less than the price of a used car. The company itself has warned that OTC trading means less liquidity, more volatility, difficulty raising capital, and potential loss of investor confidence.
A proposed merger valuing Ignite Proteomics at $150 million remains the company's last stated lifeline, but the Nasdaq Panel already dismissed that plan as unconvincing. For all practical purposes, ADTX is a cautionary tale in terminal dilution — and this delisting writes the final chapter on its Nasdaq story.